Valerylcarnitine is an endogenous short-chain acylcarnitine metabolite. Valerylcarnitine can serve as a cofactor for fatty acid oxidation, while also acting as a metabolic biomarker to indicate metabolic disorders. Valerylcarnitine can be used in research related to type 2 diabetes and newborn screening for inherited metabolic diseases[1-4].
References:
[1] Pannkuk EL, Laiakis EC, Authier S, et al. Targeted Metabolomics of Nonhuman Primate Serum after Exposure to Ionizing Radiation: Potential Tools for High-throughput Biodosimetry. RSC Adv. 2016;6(56):51192-51202.
[2] Furrer R, Jauch AJ, Nageswara Rao T, et al. Remodeling of metabolism and inflammation by exercise ameliorates tumor-associated anemia. Sci Adv. 2021 Sep 10;7(37):eabi4852.
[3] Mi Y, Yi N, Xu X, et al. Prebiotics alleviate cartilage degradation and inflammation in post-traumatic osteoarthritic mice by modulating the gut barrier and fecal metabolomics. Food Funct. 2023 May 11;14(9):4065-4077.
[4] Liu Y, Sun M, Sun J, et al. Identification of novel serum metabolic signatures to predict chronic kidney disease among Chinese elders using UPLC-Orbitrap-MS. J Nutr Health Aging. 2024 Mar;28(3):100036.
Valerylcarnitine是一种内源性短链酰基肉碱代谢物。Valerylcarnitine可作为脂肪酸氧化的辅助因子，同时通过作为代谢标志物来指示代谢异常。Valerylcarnitine可用于2型糖尿病和新生儿遗传代谢病筛查的相关研究[1-4]。